Levin Capital Strategies, L.P. Summit Therapeutics Inc. Transaction History
Levin Capital Strategies, L.P.
- $1.03 Billion
- Q3 2024
A detailed history of Levin Capital Strategies, L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 36,176 shares of SMMT stock, worth $859,541. This represents 0.08% of its overall portfolio holdings.
Number of Shares
36,176
Previous 39,176
7.66%
Holding current value
$859,541
Previous $305,000
159.67%
% of portfolio
0.08%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
199Shares Held
76MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$580 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$260 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$188 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$129 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$82.4 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.78B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...